AR066970A1 - Derivado de 17 beta-ciano-18a-homo-19-nor-androst-4- eno, su uso y medicamento que lo contiene - Google Patents
Derivado de 17 beta-ciano-18a-homo-19-nor-androst-4- eno, su uso y medicamento que lo contieneInfo
- Publication number
- AR066970A1 AR066970A1 ARP080102498A ARP080102498A AR066970A1 AR 066970 A1 AR066970 A1 AR 066970A1 AR P080102498 A ARP080102498 A AR P080102498A AR P080102498 A ARP080102498 A AR P080102498A AR 066970 A1 AR066970 A1 AR 066970A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- group
- forming
- double bond
- androst
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 3
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000017657 Menopausal disease Diseases 0.000 abstract 1
- 229940083712 aldosterone antagonist Drugs 0.000 abstract 1
- 230000001327 anti-mineralocorticoid effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 230000003152 gestagenic effect Effects 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- -1 hydroxymethylene Chemical group 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/007—3 membered carbocyclic rings in position 6-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007027636A DE102007027636A1 (de) | 2007-06-12 | 2007-06-12 | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066970A1 true AR066970A1 (es) | 2009-09-23 |
Family
ID=38858372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102498A AR066970A1 (es) | 2007-06-12 | 2008-06-12 | Derivado de 17 beta-ciano-18a-homo-19-nor-androst-4- eno, su uso y medicamento que lo contiene |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20090048218A1 (enExample) |
| EP (1) | EP2178899B1 (enExample) |
| JP (1) | JP2010529152A (enExample) |
| KR (1) | KR20100017780A (enExample) |
| CN (1) | CN101679477A (enExample) |
| AR (1) | AR066970A1 (enExample) |
| AU (1) | AU2008261277A1 (enExample) |
| BR (1) | BRPI0813455A2 (enExample) |
| CA (1) | CA2689563A1 (enExample) |
| CL (1) | CL2008001721A1 (enExample) |
| DE (1) | DE102007027636A1 (enExample) |
| ES (1) | ES2397879T3 (enExample) |
| IL (1) | IL202300A0 (enExample) |
| MX (1) | MX2009013626A (enExample) |
| PA (1) | PA8784201A1 (enExample) |
| PE (1) | PE20090312A1 (enExample) |
| RU (1) | RU2010100334A (enExample) |
| TW (1) | TW200906846A (enExample) |
| UY (1) | UY31145A1 (enExample) |
| WO (1) | WO2008151745A1 (enExample) |
| ZA (1) | ZA201000185B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010066354A1 (de) * | 2008-12-12 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG |
| WO2012059594A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Pharma Aktiengesellschaft | Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity |
| WO2012116290A2 (en) * | 2011-02-25 | 2012-08-30 | Washington University | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| CA3152410A1 (en) | 2011-10-14 | 2013-04-18 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
| TR201808616T4 (tr) | 2012-12-18 | 2018-07-23 | Sage Therapeutics Inc | Nöroaktif 19-alkoksi-17-ikameli steroidler, bunların ön ilaçları ve bunları kullanan tedavi yöntemleri. |
| US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| US9365502B2 (en) | 2013-03-11 | 2016-06-14 | Washington University | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| RU2019126333A (ru) | 2013-04-17 | 2019-10-08 | Сейдж Терапьютикс, Инк. | 19-нор нейроактивные стероиды и способы их применения |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| CN113527400B (zh) | 2013-04-17 | 2024-06-28 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| WO2015010054A2 (en) * | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| AU2014308621C1 (en) | 2013-08-23 | 2022-01-06 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| SMT202000414T1 (it) | 2014-10-16 | 2020-09-10 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| MX2021004492A (es) | 2014-10-16 | 2022-12-05 | Sage Therapeutics Inc | Composiciones para el tratamiento de trastornos del snc. |
| ME03749B (me) | 2014-11-27 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a |
| DK3250210T3 (da) | 2015-01-26 | 2021-03-08 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| CA3030420C (en) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3043833A (en) * | 1961-07-14 | 1962-07-10 | Ormonoterapia Richter Spa | 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof |
| DE1183500B (de) | 1962-10-12 | 1964-12-17 | Schering Ag | Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe |
| US3579509A (en) * | 1965-06-21 | 1971-05-18 | Smith Kline French Lab | Process and 6-beta-substituted ethyl intermediates for preparing 6,6-ethylene-3-keto-delta**4 steroids |
| GB1089945A (en) * | 1965-09-23 | 1967-11-08 | British Drug Houses Ltd | Steroidal-6-spirocyclopropyl-4-en-3-ones |
| IL32699A (en) * | 1968-07-30 | 1973-06-29 | American Home Prod | 6-substituted-13-polycarbonalkyl-18,19 dinorpregn-4-en-3-ones,their preparation and pharmaceutical compositions containing them |
| FR2081561B1 (enExample) * | 1970-03-03 | 1973-04-06 | Roussel Uclaf | |
| US3705179A (en) | 1971-03-15 | 1972-12-05 | American Home Prod | Antiandrogenic steroids |
| FR2139708B1 (enExample) * | 1971-06-01 | 1974-08-23 | Roussel Uclaf | |
| US3994937A (en) * | 1972-02-11 | 1976-11-30 | Schering Aktiengesellschaft | 15α,16α-Methylene-4-estren-17β-ols |
| BE795241A (fr) | 1972-02-11 | 1973-08-09 | Schering Ag | 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation |
| NL7701384A (nl) | 1977-02-10 | 1978-08-14 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks. |
| DE2922500A1 (de) | 1979-05-31 | 1980-12-04 | Schering Ag | 6 beta .7 beta |
| US4252800A (en) * | 1979-10-05 | 1981-02-24 | United States Of America | 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals |
| US4544554A (en) * | 1983-09-26 | 1985-10-01 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| DE3402329A1 (de) | 1984-01-20 | 1985-08-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| EP0785211A1 (en) * | 1996-01-22 | 1997-07-23 | Laboratoire Theramex | New substituted 19-nor-pregnane derivatives |
| DE19651000A1 (de) | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
| DE102004063864A1 (de) * | 2004-12-30 | 2006-07-13 | Schering Ag | 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
-
2007
- 2007-06-12 DE DE102007027636A patent/DE102007027636A1/de not_active Withdrawn
-
2008
- 2008-06-04 WO PCT/EP2008/004428 patent/WO2008151745A1/de not_active Ceased
- 2008-06-04 CA CA002689563A patent/CA2689563A1/en not_active Abandoned
- 2008-06-04 KR KR1020097025931A patent/KR20100017780A/ko not_active Withdrawn
- 2008-06-04 ES ES08758989T patent/ES2397879T3/es active Active
- 2008-06-04 JP JP2010511525A patent/JP2010529152A/ja active Pending
- 2008-06-04 CN CN200880020040A patent/CN101679477A/zh active Pending
- 2008-06-04 EP EP08758989A patent/EP2178899B1/de not_active Not-in-force
- 2008-06-04 BR BRPI0813455-3A2A patent/BRPI0813455A2/pt not_active Application Discontinuation
- 2008-06-04 MX MX2009013626A patent/MX2009013626A/es not_active Application Discontinuation
- 2008-06-04 AU AU2008261277A patent/AU2008261277A1/en not_active Abandoned
- 2008-06-04 RU RU2010100334/04A patent/RU2010100334A/ru not_active Application Discontinuation
- 2008-06-11 PE PE2008000992A patent/PE20090312A1/es not_active Application Discontinuation
- 2008-06-11 PA PA20088784201A patent/PA8784201A1/es unknown
- 2008-06-11 UY UY31145A patent/UY31145A1/es not_active Application Discontinuation
- 2008-06-11 US US12/137,122 patent/US20090048218A1/en not_active Abandoned
- 2008-06-11 TW TW097121799A patent/TW200906846A/zh unknown
- 2008-06-11 CL CL2008001721A patent/CL2008001721A1/es unknown
- 2008-06-12 AR ARP080102498A patent/AR066970A1/es unknown
-
2009
- 2009-11-24 IL IL202300A patent/IL202300A0/en unknown
-
2010
- 2010-01-11 ZA ZA2010/00185A patent/ZA201000185B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009013626A (es) | 2010-01-20 |
| RU2010100334A (ru) | 2011-07-20 |
| CL2008001721A1 (es) | 2008-12-19 |
| TW200906846A (en) | 2009-02-16 |
| BRPI0813455A2 (pt) | 2014-12-23 |
| IL202300A0 (en) | 2010-06-30 |
| PA8784201A1 (es) | 2009-01-23 |
| KR20100017780A (ko) | 2010-02-16 |
| EP2178899A1 (de) | 2010-04-28 |
| DE102007027636A1 (de) | 2008-12-18 |
| ZA201000185B (en) | 2011-03-30 |
| US20090048218A1 (en) | 2009-02-19 |
| CA2689563A1 (en) | 2008-12-18 |
| JP2010529152A (ja) | 2010-08-26 |
| CN101679477A (zh) | 2010-03-24 |
| PE20090312A1 (es) | 2009-04-09 |
| AU2008261277A1 (en) | 2008-12-18 |
| ES2397879T3 (es) | 2013-03-12 |
| WO2008151745A1 (de) | 2008-12-18 |
| UY31145A1 (es) | 2009-01-30 |
| EP2178899B1 (de) | 2012-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8784201A1 (es) | Derivado de 17b-ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene | |
| AR066971A1 (es) | Derivado de 17beta-ciano-19-nor-androst-4-eno- su uso y medicamento que lo contiene | |
| CO6251271A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| PE20210398A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados | |
| AR063240A1 (es) | Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas. | |
| AR083169A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| ECSP077228A (es) | Proceso para la preparación de derivados de estrona y de estradiol sustituidos en la posición 2 | |
| BRPI0912171A8 (pt) | Composto ativador de receptor de glicocorticoide, e, composição | |
| AR056025A1 (es) | Compuestos de imidazol sustituidos como inhibidores de ksp | |
| CO5570696A2 (es) | 1-amino-alquilciclohexanos insaturados como antagonistas de los receptores nmda, 5ht3 y nicotinico neuronal | |
| ECSP10010315A (es) | Derivados de 19-nor-esteroide que tiene un grupo 15 ,16 -metileno y un anillo de 17,17-espirolactona saturado, su uso y medicamentos que los comprenden | |
| AR069700A1 (es) | Derivados de azetidina,composiciones farmaceuticas que los comprenden, metodo de preparacion, intermediarios de sintesis,y usos de los mismos en el tratamiento o prevencion de trastornos psiquiatricos , del sistema inmune y gastrointestinales, entre otros. | |
| AR069963A1 (es) | Derivado 15, 16-metilen-17- (1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene | |
| WO2008152112A3 (de) | 17ß-CYANO-19-ANDROST-4-EN-DERIVAT, DESSEN VERWENDUNG UND DAS DERIVAT ENTHALTENDE ARZNEIMITTEL | |
| GEP20074256B (en) | Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing | |
| AR069965A1 (es) | Derivado de (gamma)-lactona de esteroide de acido 15, 16 -metilen-17-hidroxi-19-nor-21-carboxilico, su uso para preparar un medicamento que lo contiene y medicamento que contiene al compuesto | |
| PA8809701A1 (es) | Derivado de y-lactona del esteroide del ´cido 17-hidroxi-19-nor-21-carboxílico, su uso y el medicamento que lo contiene | |
| AR052258A1 (es) | Derivados de fenilpiperazinas con una afinidad combinada para receptores de dopamina - d2 y sitios de reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del sistema nervioso central. | |
| AR074728A1 (es) | Uso de derivados 17-beta-ciano-18a-homo-19-nor-androst-4-eno para preparar un medicamento en forma de deposito para la aplicacion parenteral, asi como medicamentos de deposito que contienen derivados de 17beta-ciano-18a-homo-19-nor-androst-4-eno para la aplicacion parenteral | |
| AR074729A1 (es) | Uso de derivados de 17beta-ciano-19-nor-androst-4-eno para la obtencion de un medicamento en forma de deposito para la aplicacion parenteral y medicamentos de deposito que contienen derivados de 17beta-ciano-19-nor-androst-4-eno para aplicacion parenteral | |
| TN2018000287A1 (en) | Use of stiripentol and their derivatives for decreasing urinary oxalate concentration in an individual | |
| UY31582A1 (es) | Derivado de 17- ( 1' - propenil) - 17-3' - oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen | |
| CU20100137A7 (es) | Derivados de 19-nor-esteroide que tiene un grupo 15, 16-metileno y un anillo de 17, 17-espirolactona saturado, su uso y medicamentos que los comprenden | |
| AR074730A1 (es) | Uso de derivados de 17beta-ciano-19-androst-4-eno para la obtencion de un medicamento en forma de deposito para uso parenteral y a medicamentos de deposito que contienen derivados de 17beta-ciano-19-androst-4-eno para aplicacion parenteral | |
| AR057748A1 (es) | Derivados de 2,3 dihidroindol. composiciones farmaceuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |